Clinical characteristics and outcomes of HIV positive patients with lymphoma in an oncological reference center in Mexico City

Cardenas-Ortega, Andrea; Ramírez-Ibarguen, Ana Florencia; Rivera‐Buendía, Frida; Pérez‐Jimenez, Carolina; Volkow-Fernández, Patricia; Martin-Onraët, Alexandra

doi:10.1097/md.0000000000022408

Cited by 4 publications

(5 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, HIV patients with HL have a relatively higher T CD4 + count and a lower viral load at diagnosis than patients with non-HL. [ 28 ] It has been suggested that the use of interperiod ART and the late timing of HL diagnosis are directly related. There are several particular characteristics of HL associated with HIV, including: advanced-stage disease (Ann Harbor III-IV), frequent constitutional symptoms, less favorable histology, more frequent bone marrow involvement, and worse prognosis compared to immunocompetent individuals.…”

Section: Discussionmentioning

confidence: 99%

Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis

Fagundes¹,

Mederios²,

Souza

et al. 2022

Medicine

View full text Add to dashboard Cite

Background: Hodgkin lymphoma (HL) is a rare lymphoproliferative disorder that occurs in about 10% of all cancer cases. Human immunodeficiency virus (HIV) is associated with an increased occurrence of a wide range of cancers, including HL due to progressive immunosuppression and co-infection with oncogenic viruses. However, the aim of this systematic review is to obtain evidence about the impact of the HIV infection in HL individuals. Methods: We will obtain studies through PubMed, Embase, CINAHL, LILACS, CENTRAL, Web of Science, Scopus, Cochrane Library, and Google Scholar databases. The inclusion criteria will be observational studies (sectional, cohort, and case-control) that describe the impact of the HIV infection in HL individuals. Outcomes of interest include mortality, prevalence, causes of hospitalization, time between HIV diagnosis and HL diagnosis in days, comorbidities (systemic hypertension, diabetes mellitus, metabolic syndrome, others), T CD4 + cells/mm 3 at HIV diagnosis and at HL diagnosis, viral load (log10 copies/mL) at HL diagnosis, and history of treatment abandon. Two reviewers, independently, will extract the data from each included study. Meta-analysis will then be carried out using fixed-effects or random-effects model, using the mean difference for continuous outcomes and the relative risk for dichotomous outcomes. Risk of bias will be assessed using the Newcastle–Ottawa Scale. The quality of evidence for each outcome will be assessed using Grading of Recommendations Assessment, Development and Evaluation methodology. Review Manager V.5.3.5 will be used for synthesis and subgroup analysis. To assess heterogeneity, we will compute the I 2 statistics. Additionally, a quantitative synthesis will be performed if the included studies are sufficiently homogenous. Ethics and dissemination: This study will be a review of the published data, and thus it is not necessary to obtain ethical approval. The findings of this systematic review will be published in a peer-reviewed journal. PROSPERO registration number: CRD42021289520

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis

Fagundes¹,

Mederios²,

Souza

et al. 2022

Medicine

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

“…They usually present to care with severe immunosuppression; most of them have a recent HIV diagnosis, have not yet been linked to medical care and are naïve to antiretroviral therapy (ART) at the time of cancer diagnosis. 3,4 This study aimed to describe the characteristics of patients who were received at the Cancer and AIDS Clinic of INCan, before and after March 2020, and to compare their clinical conditions upon first consultation, 30 and 90-day mortality.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 pandemic in the care of people living with HIV and cancer at an oncologic center in Mexico

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background People living with HIV(PLWH) and cancer are among the most vulnerable patients and require constant access to medical services. We compared the characteristics of PLWH and cancer in Mexico, before and during the COVID-19 pandemic. Methods Patients admitted 1 year before (pre-pandemic) and 1 year after the start of the pandemic (pandemic) were included. Clinical characteristics, HIV-related variables, and 90-day mortality were compared. Data are described a proportions (N,%) and central tendency measures. A multiple regression model for variables associated with 90-day mortality was performed. Results Seventy-nine patients were seen in the pre-pandemic period; 92 during the pandemic. Main diagnoses were Kaposi Sarcoma and lymphoma. CD4+ cell count at diagnosis was lower during the pandemic: 81 cells/mm3 vs. 128 cells/mm3, p = .035. CD4+<100 cells/mm3 at first consultation increased from 41% to 58% during the pandemic ( p = .041). Only BMI <20 kg/m2 was associated to death (aOR 8.27, 95%CI 1.74-39.25) ( p = .008). The pandemic period was not associated with a higher 90-day mortality. Conclusions PLWH and cancer presented to care with advanced disease overall. This was more pronounced during the pandemic period. Mortality was associated with AIDS-related variables regardless of study period. This underscores the need for strategies to maintain in-person access to health-care services for PLWH.

show abstract

“…Therefore, a significant number of patients are ART‐naïve and have low CD4 counts at the time of lymphoma diagnosis. This coupled with lack of social support contributes to poor outcomes similar to that of pre‐HAART era 5–7 …”

Section: Introductionmentioning

confidence: 99%

“…This coupled with lack of social support contributes to poor outcomes similar to that of pre-HAART era. [5][6][7] In the HAART era, outcomes of AIDS-related diffuse large B-cell lymphoma (DLBCL) when treated with CHOP (cyclophosphamide, hydroxydaunorubicin, vincristine and prednisone) did show an improvement; however, remained inferior to their immunocompetent counterparts. 8 Addition of rituximab to CHOP, failed to show improvement in overall survival (OS) of these patients.…”

Section: Introductionmentioning

confidence: 99%

Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)‐associated lymphomas

et al. 2022

View full text Add to dashboard Cite

Management of acquired immunodeficiency syndrome (AIDS)-related diffuse large B-cell (DLBCL) and plasmablastic lymphomas (PBL) poses significant challenges. The evidence supports use of dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) with or without rituximab as first-line therapy.The need for central venous access, growth factors and significant toxicities limits its use in resource-constrained settings. To address these challenges, we have developed a novel regimen, CVEP (cyclophosphamide, vinblastine, etoposide, and prednisolone) based on the pharmacodynamic principles of dose-adjusted EPOCH. This singlecentre phase II study evaluated the efficacy and safety of CVEP regimen in patients with de novo systemic AIDS-related DLBCL and PBL. The primary objective was complete response (CR) rates as assessed by positron emission tomography-computed tomography. The secondary objectives were incidence of Grade 3/4 toxicities, toxicities requiring hospitalisation, and disease-free survival. From May 2011 to February 2017, 42 patients were enrolled. At the end of therapy the CR rates were 69% (29/42) in

show abstract

Clinical characteristics and outcomes of HIV positive patients with lymphoma in an oncological reference center in Mexico City

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 24 publications

Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis

Impact of the HIV infection in Hodgkin lymphoma individuals: A protocol for systematic review and meta analysis

Impact of COVID-19 pandemic in the care of people living with HIV and cancer at an oncologic center in Mexico

Phase II trial of a novel chemotherapy regimen CVEP (cyclophosphamide, vinblastine, etoposide and prednisolone) for acquired immunodeficiency syndrome (AIDS)‐associated lymphomas

Contact Info

Product

Resources

About